WPD focuses on developing biological and chemical molecules involved in targeted therapy for brain glioma and other central nervous system cancers.
WPD has 4 novel drug candidates with 1 that in in clinical development stage and 3 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University. WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.